TG Therapeutics Inc (TGTX) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

TG Therapeutics Inc

NASDAQ | TGTX

38.32

USD

+0.11 (+0.29%)

AT CLOSE (AS OF Apr 17, 2025)

$6B

MARKET CAP

255.47

P/E Ratio

0.15

EPS

$43

52 Week High

$13

52 Week Low

LIFE SCIENCES

Sector

TGTX Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

TGTX Technicals

Tags:

TGTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$291M
Total Revenue	$329M
Cost Of Revenue	$38M
Costof Goods And Services Sold	$38M
Operating Income	$42M
Selling General And Administrative	$154M
Research And Development	$94M
Operating Expenses	$249M
Investment Income Net	-
Net Interest Income	-$24M
Interest Income	-
Interest Expense	$24M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$280K
Income Before Tax	$26M
Income Tax Expense	$2.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	$23M
Comprehensive Income Net Of Tax	-
Ebit	$50M
Ebitda	$50M
Net Income	$23M

Revenue & Profitability

Earnings Performance

TGTX Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$578M
Total Current Assets	$566M
Cash And Cash Equivalents At Carrying Value	$180M
Cash And Short Term Investments	$180M
Inventory	$110M
Current Net Receivables	-
Total Non Current Assets	$11M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	$799K
Investments	-
Long Term Investments	$808K
Short Term Investments	$131M
Other Current Assets	$16M
Other Non Current Assets	-
Total Liabilities	$355M
Total Current Liabilities	$91M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$1.2M
Total Non Current Liabilities	$265M
Capital Lease Obligations	$9.3M
Long Term Debt	$244M
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$254M
Other Current Liabilities	$78M
Other Non Current Liabilities	-
Total Shareholder Equity	$222M
Treasury Stock	-
Retained Earnings	-$1.5B
Common Stock	$156K
Common Stock Shares Outstanding	$160M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$41M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$68K
Capital Expenditures	$45K
Change In Receivables	-
Change In Inventory	-$67M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$129M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-$8.8M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$23M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$291M
Total Revenue	$329M
Cost Of Revenue	$38M
Costof Goods And Services Sold	$38M
Operating Income	$42M
Selling General And Administrative	$154M
Research And Development	$94M
Operating Expenses	$249M
Investment Income Net	-
Net Interest Income	-$24M
Interest Income	-
Interest Expense	$24M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$280K
Income Before Tax	$26M
Income Tax Expense	$2.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	$23M
Comprehensive Income Net Of Tax	-
Ebit	$50M
Ebitda	$50M
Net Income	$23M

TGTX News

TGTX Profile

TG Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

TGTX $38.32 (+0.29%) Quote details